June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Myopia progression before, during and after the COVID-19 pandemic in North American children
Author Affiliations & Notes
  • Marcella McParland
    Commercial, SightGlass Vision Inc, Palo Alto, California, United States
  • Deborah Laughton
    Commercial, SightGlass Vision Inc, Palo Alto, California, United States
  • Jennifer Hill
    Commercial, SightGlass Vision Inc, Palo Alto, California, United States
  • Vanessa Tasso
    Commercial, SightGlass Vision Inc, Palo Alto, California, United States
  • Jay Neitz
    Genetics, University of Washington, Seattle, Washington, United States
  • Maureen Neitz
    Genetics, University of Washington, Seattle, Washington, United States
  • Thomas Chalberg
    Commercial, SightGlass Vision Inc, Palo Alto, California, United States
  • Footnotes
    Commercial Relationships   Marcella McParland SightGlass Vision Inc., Code E (Employment), CooperVision Ltd, Code E (Employment); Deborah Laughton SightGlass Vision Inc., Code E (Employment); Jennifer Hill SightGlass Vision Inc., Code E (Employment); Vanessa Tasso SightGlass Vision Inc., Code E (Employment); Jay Neitz SightGlass Vision Inc., Code I (Personal Financial Interest), SightGlass Vision Inc., Code P (Patent); Maureen Neitz SightGlass Vision Inc., Code I (Personal Financial Interest), SightGlass Vision Inc., Code P (Patent); Thomas Chalberg SightGlass Vision Inc., Code C (Consultant/Contractor), Genascence Corp, Code E (Employment), SightGlass Vision Inc., Code O (Owner), Exhaura Ltd, Code O (Owner), IrenixMedical, Code O (Owner), SightGlass Vision Inc., Code P (Patent), Exhaura Ltd, Code P (Patent), IrenixMedical, Code P (Patent)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 815. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Marcella McParland, Deborah Laughton, Jennifer Hill, Vanessa Tasso, Jay Neitz, Maureen Neitz, Thomas Chalberg; Myopia progression before, during and after the COVID-19 pandemic in North American children. Invest. Ophthalmol. Vis. Sci. 2023;64(8):815.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the effect of social restrictions during the COVID-19 pandemic on myopia progression in North American children.

Methods : Myopic children aged 6 to 10 years were enrolled in CYPRESS (NCT03623074): a double-masked, randomized, controlled clinical trial to evaluate the safety and efficacy of DOT spectacle lenses across 14 North American sites. Participant enrolment began in July 2018. The 24 to 36-month visits (from March 2020 to April 2022) coincided with COVID-19 social restrictions in North America. The 42-month visit window was January 2022 to September 2022 (when restrictions had ceased). Axial Length (AL) and Spherical Equivalent Refraction (SER) were measured at 0, 12, 24, 36 and 42 months.
AL progression of the CYPRESS Control group (n=42; wearing standard single vision spectacles) was compared to age-matched myopic AL growth data from the Orinda Longitudinal Study of Myopia (OLSM; collected between 1989 to 2001) to evaluate the potential impact of the COVID-19 pandemic.

Results : Pre-pandemic, Control group mean change in AL and SER (± SD) from 0-12 months was 0.32 ± 0.17 mm and -0.58 ± 0.52 D, respectively. AL and SER progression nearly halved during the pandemic (from 12-24 months AL 0.23 ± 0.18 mm, SER -0.35 ± 0.41 D; from 24-36 months AL 0.20 ± 0.15 mm, SER -0.34 ± 0.33 D). The children reported altered school routines during this period. Post-pandemic, AL and SER progression from 36-42 months (in 6 months) was 0.11 ± 0.09 mm and -0.22 ± 0.26 D, respectively. Comparison with age-matched AL growth data from the OLSM showed a difference between means (CYPRESS – OLSM) of +0.05 mm pre-pandemic, -0.08 mm during the pandemic and 0.00 mm post-pandemic.

Conclusions : The progression of myopia among CYPRESS Control children decreased during the COVID-19 pandemic. Changes in lifestyle, behaviour and schooling during the COVID-19 pandemic may have contributed to reduced myopia progression

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×